Radiology News
-
Showcase
Mobile Mammography
bout two years after the outbreak of COVID-19, many resources are still being used in the fight against this new virus. Nevertheless, the number of breast cancer cases in Italy are still very high: according to the report “The numbers of cancer in Italy”, published by AIRTUM and AIOM, in 2020 about 55.000 new cases were diagnosed in Italy among women (as of today, estimates for 2021 ...
-
Showcase
Koning Begins FDA Clinical Screening Trial in Daytona Beach, Florida
DAYTONA BEACH, Fla., Nov. 1, 2021 /PRNewswire/ -- Koning begins an FDA screening trial this month for their no-compression, Isotropic, 3-dimensional breast imaging device. The company received FDA PMA approval for commercial, diagnostic use in 2017. Since then, the Koning Breast CT (KBCT) has been installed in clinics and universities in the US and globally. "This FDA screening trial is a major ...
-
Showcase
RTsafe and Biomedic Medical Group sign exclusive agreement for distribution
RTsafe, a medical technology company focused on improving the safety and accuracy of radiotherapy for cancer and other medical conditions, today announced that Biomedic Medical Group will be the exclusive distributor of RTsafe’s products in China. We are delighted to announce this new collaboration and looking forward to provide our products to the Chinese radiotherapy professionals. ...
By RTsafe
-
AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the completion of patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV). APEX-AV is a ...
-
Bayer driving innovation in radiology with new research across the portfolio presented at ECR
Featured presentations include development compound gadoquatrane, a novel contrast agent for MRI Further research explores potential of AI and digital advances in medical imaging Bayer announced today that new data from the company’s advanced radiology portfolio will be presented at the 2023 European Congress of Radiology (ECR), taking place from March 1-5 in Vienna, Austria. The ...
By Bayer AG
-
Bayer completes acquisition of Blackford Analysis Ltd.
Closing follows announcement of acquisition on January 18, 2023 Acquisition bolsters Bayer’s position in digital medical imaging Blackford will utilize Bayer’s well established “arm’s length” operating model to preserve the company’s entrepreneurial culture Bayer today announced that the company has completed the acquisition of the global strategic ...
By Bayer AG
-
Ultravist by Bayer now approved for contrast-enhanced mammography in EU
Ultravist-300, -370 receives green light for indication extension for use in contrast-enhanced mammography (CEM) in a European Workshare Procedure CEM is emerging modality combining digital mammography with the administration of a contrast agent Strategically expands Bayer’s portfolio in breast imaging, including contrast agents and injectors Bayer announced today that its ...
By Bayer AG
-
Bayer acquires Blackford Analysis Ltd. bolstering the company’s position in digital medical imaging
Acquisition is part of Bayer’s innovation strategy in radiology Blackford Analysis provides cutting-edge radiology AI (artificial intelligence) platform technology Following closing of the acquisition, Blackford Analysis to become part of Bayer’s well established “arm’s length” operating model to preserve the company’s entrepreneurial culture Bayer today ...
By Bayer AG
-
Inspirata Accelerates Its Growth as a Leading Provider of AI/NLP Technology in Oncology Informatics
Inspirata Inc. and FUJIFILM Corporation signed an asset purchase agreement for Fujifilm to acquire Inspirata’s Dynamyx® digital pathology technology, employees and customers, building off the proven success of the established partnership between the companies in UK and Europe. This milestone allows the Digital Pathology business to flourish with a partner who has the breadth, depth and ...
-
BARDA-funded Intranasal Antibody Cocktail for COVID-19 Shows Promise in a Preclinical Study
Lumen Bioscience — a clinical stage biopharmaceutical company developing biologic drugs for highly prevalent diseases — announced today preliminary results from a Biomedical Advanced Research and Development Authority (BARDA)-supported effort to develop an intranasal formulation of its drug candidate, LMN-301. This drug, produced in spirulina, contains an antibody cocktail for ...
-
Antengene Highlights Encouraging ATG-008 Efficacy Results From TORCH-2 Study in Combination with PD-1 Antibody in Relapsed/Metastatic Cervical Cancer
An objective response rate (ORR) of 52.4% was observed in relapsed or metastatic cervical cancer in Phase I/II TORCH-2 Study of ATG-008 (onatasertib) in combination with toripalimab, regardless of PD-L1 status Study builds on promising results of Phase II TORCH monotherapy study in HBV+ patients with unresectable hepatocellular carcinoma (HCC) which demonstrated an ORR of 16.7% in the 45 mg ...
-
Ready to go mobile
The Arktis Radiation Detectors MODES kit is designed to detect and identify radiological threats. The system can work either deployed in vehicles or as a stand-alone static monitor. The internal processing unit manages the real-time ambient spectrum. Also, our FPG drone technology can be integrated ...
-
Prof. Krestin Joins Fluidda’S Board of Directors
INTRODUCTION Gabriel Krestin received his MD from the University of Cologne, Germany where he also specialized in radiology, in 1981 and his PhD (Habilitation) in 1989. From 1990–1997, he worked at the University Hospital in Zürich/CH, including a period as acting chairman of the Department of Radiology. In 1997 he moved to Erasmus MC in Rotterdam, Netherlands where he was the ...
By Fluidda
-
SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox
NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of TPOXX to treat monkeypox. In recent weeks, randomized, placebo-controlled clinical trials were initiated in ...
-
Enalare Therapeutics Receives Orphan Drug Designation From the U.S. FDA on ENA-001 for the Treatment of Apnea of Prematurity (AoP)
ENA-001, a New Chemical Entity (NCE) with a novel mechanism of action as an agnostic respiratory stimulant, has previously been granted Rare Pediatric Disease designation for the Treatment of AoP by the FDA, with eligibility for a priority review voucher (PRV). The compound is also being developed by Enalare for the treatment of post-operative respiratory depression and community drug overdose. ...
-
SIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX®
NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Department of Defense (DoD) awarded a new contract to SIGA for the procurement of up to $10.7 million of oral TPOXX (Contract number: W911SR22C0051), of which $5.1 million of oral TPOXX is ...
-
ScreenPoint Medical showcases world leading Transpara powered by FusionAI at RSNA
It follows a year of major achievements for the organisation with Transpara which is now installed in health care facilities both across the US and in over 25 countries worldwide. The success of FDA cleared Transpara AI has been marked by a record number of peer reviewed papers and well over 2,000,000 mammograms being read by this unique system. Transpara's developers, ScreenPoint Medical is ...
-
Integrating Fusion Biopsies into Your Practice II
Targeted MRI-US fusion biopsy is an emerging technology with the potential to change the standard of care for diagnosis and treatment. It combines the accuracy of MRI with the real-time monitoring of ultrasound to detect more clinically significant cancer, while preventing unnecessary biopsies. Unlike standard systematic biopsy, fusion can track lesions over time with imaging or repeat ...
-
Belgian scale-up Oncomfort raises €10 million in Series A funding co-led by Debiopharm and Crédit Mutuel Innovation
Oncomfort, the Belgian inventor of and leader in Digital Sedation - a new method for relieving patients’ pain and anxiety without medication - today announces the completion of a €10 million Series A funding round co-led by two prominent institutional investors: Debiopharm and Crédit Mutuel Innovation. Oncomfort plans to use this investment to further develop its innovative ...
By Oncomfort
-
ABK Biomedical announces FDA 510(k) clearance of Easi-Vue™ embolic microspheres for the embolization of arteriovenous malformations and hypervascular tumors
ABK Biomedical, Inc., an innovative medical device company dedicated to the research, development, and commercialization of advanced imageable embolic therapies, announces FDA 510(k) clearance of Easi-Vue embolic microspheres for the treatment of patients suffering from arteriovenous malformations and hypervascular tumors. Arteriovenous malformations (AVMs) occur when capillaries, veins, and ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you